China NMPA Drug Inspection - Lijiang Huali Biotechnology Development Co., Ltd. - honeysuckle
China NMPA drug inspection for Lijiang Huali Biotechnology Development Co., Ltd. published December 10, 2019. Drug: honeysuckle. The Yunnan Provincial Drug Administration issued its "2019 Issue 2 Announcement on Substandard Drug Quality" on December
One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.
China NMPA drug inspection for Lijiang Huali Biotechnology Development Co., Ltd. published December 10, 2019. Drug: honeysuckle. The Yunnan Provincial Drug Administration issued its "2019 Issue 2 Announcement on Substandard Drug Quality" on December
Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox